journal
Journals Hematology - the Education Pro...

Hematology - the Education Program of the American Society of Hematology

https://read.qxmd.com/read/36485171/thilagar-b-beidoun-m-rhoades-r-kaatz-s-covid-19-and-thrombosis-searching-for-evidence-hematology-am-soc-hematol-educ-program-2021-2021-621-627
#1
B Thilagar, M Beidoun, R Rhoades, S Kaatz
No abstract text is available yet for this article.
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485170/burnett-ae-ragheb-b-kaatz-s-perioperative-consultative-hematology-can-you-clear-my-patient-for-a-procedure-hematology-am-soc-hematol-educ-program-2021-2021-521-528
#2
A E Burnett, B Ragheb, S Kaatz
No abstract text is available yet for this article.
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485169/williams-km-noninfectious-complications-of-hematopoietic-cell-transplantation-hematology-am-soc-hematol-educ-program-2021-2021-578-586
#3
K M Williams
No abstract text is available yet for this article.
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485167/acute-pain-episodes-acute-chest-syndrome-and-pulmonary-thromboembolism-in-pregnancy
#4
JOURNAL ARTICLE
Eugenia Vicky Asare, Michael R DeBaun, Edeghonghon Olayemi, Theodore Boafor, Samuel A Oppong
Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In both high- and low-income countries, there is an 11-fold increased risk of maternal death and a 4-fold increased risk of perinatal death. We highlight the epidemiology of SCD-specific and obstetric complications commonly seen during pregnancy in SCD and propose definitions for acute pain and acute chest syndrome (ACS) episodes during pregnancy. We conducted a systematic review of the recent obstetric and hematology literature using full research articles published within the last 5 years that reported outcomes in pregnant women with SCD...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485166/evidence-based-management-of-pregnant-women-with-sickle-cell-disease-in-high-income-countries
#5
JOURNAL ARTICLE
Eugene Oteng-Ntim, Panicos Shangaris
Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2)...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485165/perioperative-hemostasis-for-patients-with-hemophilia
#6
JOURNAL ARTICLE
Jacqueline N Poston, Rebecca Kruse-Jarres
No abstract text is available yet for this article.
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485164/clinical-screening-for-ph-like-all-and-the-developing-role-of-tkis
#7
JOURNAL ARTICLE
Thai Hoa Tran, Sarah K Tasian
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a common subtype of B-lineage acute lymphoblastic leukemia (B-ALL) with increasing frequency across the age spectrum. Characterized by a kinase-activated gene expression profile and driven by a variety of genetic alterations involving cytokine receptors and kinases, Ph-like ALL is associated with high rates of residual disease and relapse in patients treated with conventional chemotherapy. In this case-based review, we describe the biology of the 2 major ABL-class and JAK pathway genetic subtypes of Ph-like ALL, discuss current diagnostic testing methodologies, and highlight targeted inhibitor and chemo/immunotherapy approaches under clinical investigation in children, adolescents, and adults with these high-risk leukemias...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485163/new-strategies-for-mismatched-unrelated-donor-mmud-hematopoietic-cell-transplant-hct
#8
JOURNAL ARTICLE
Shukaib Arslan, Monzr M Al Malki
With increasing numbers of patients with hematologic malignancies requiring allogeneic hematopoietic cell transplant (HCT), including minority racial and ethnic groups, the limited availability of matched related donors and matched unrelated donors remains a significant obstacle. Hence, the use of alternative donors such as haploidentical and mismatched unrelated donors (MMUDs) is on the rise. Herein, we present case studies to outline a rational and stepwise approach with a focus on the use of MMUD for HCT in patients with hematologic malignancies...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485162/hematology-2022-what-is-complete-hla-match-in-2022
#9
JOURNAL ARTICLE
Stephen R Spellman
Allogeneic hematopoietic cell transplantation (alloHCT) often represents the only curative treatment for various malignant and nonmalignant disorders. Initially, the only suitable donors were considered human leukocyte antigen (HLA)-matched or partially matched relatives. The founding of international unrelated donor and umbilical cord blood registries expanded unrelated donor options and access for patients. In the absence of a matched sibling donor (MSD) with 13% to 51% availability, the current consensus recommends use of a matched unrelated donor (MUD) at HLA-A, B, C, and DRB1 with consideration of matching at HLA-DPB1 and -DQB1...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485161/cold-aiha-and-the-best-treatment-strategies
#10
JOURNAL ARTICLE
Jenny McDade Despotovic, Taylor Olmsted Kim
Cold-reactive autoimmune hemolytic anemia (AIHA) is rare among the hemolytic anemias. It results when 1 of a variety of processes causes the generation of immunoglobulin M (IgM) autoantibodies against endogenous erythrocytes, resulting in complement activation and predominantly intravascular hemolysis. Cold AIHA is typically a primary lymphoproliferative disorder with marrow B-cell clones producing pathogenic IgM. More rarely, secondary cold AIHA (cAIHA) can develop from malignancy, infection, or other autoimmune disorders...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485160/risk-stratifying-mds-in-the-time-of-precision-medicine
#11
JOURNAL ARTICLE
Mario Cazzola
Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by morphologic dysplasia, persistent cytopenia, and a variable risk of evolution to acute myeloid leukemia (AML). Risk stratification is crucial in a patient-centered approach to the treatment of MDS. Based on hematologic parameters and cytogenetic abnormalities, the Revised International Prognostic Scoring System is currently used for this purpose. In the past years, the use of massively parallel DNA sequencing has clarified the genetic basis of MDS and has enabled development of novel diagnostic and prognostic approaches...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485159/high-or-low-assessing-disease-risk-in-multiple-myeloma
#12
JOURNAL ARTICLE
Timothy Martin Schmidt
Based upon the development of highly effective therapies such as immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies that target plasma cell biology, a dramatic improvement in overall survival has been observed for most patients with multiple myeloma (MM) over the past 2 decades. Although it is now commonplace for many patients with myeloma to live in excess of 10 years after diagnosis, unfortunately a large subset of patients continues to experience an aggressive disease course marked by substantial morbidity and early mortality...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485158/available-and-emerging-therapies-for-bona-fide-advanced-systemic-mastocytosis-and-primary-eosinophilic-neoplasms
#13
REVIEW
Jason Gotlib
The historically poor prognosis of patients with advanced systemic mastocytosis (AdvSM) and primary eosinophilic neoplasms has shifted to increasingly favorable outcomes with the discovery of druggable targets. The multikinase/KIT inhibitor midostaurin and the highly selective KIT D816V inhibitor avapritinib can elicit marked improvements in measures of mast cell (MC) burden as well as reversion of MC-mediated organ damage (C-findings) and disease symptoms. With avapritinib, the achievement of molecular remission of KIT D816V and improved survival compared with historical therapy suggests a potential to affect disease natural history...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485157/modern-management-of-fanconi-anemia
#14
REVIEW
Carlo Dufour, Filomena Pierri
In this review, we present a clinical case report and discussion to outline the importance of long-term specific Fanconi anemia (FA) monitoring, and we discuss the main aspects of the general management of patients with FA and clinical complications. While several nontransplant treatments are currently under evaluation, hematopoietic stem cell transplantation (HSCT) remains the only therapeutic option for bone marrow failure (BMF). Although HSCT outcomes in patients with FA have remarkably improved over the past 20 years, in addition to the mortality intrinsic to the procedure, HSCT increases the risk and accelerates the appearance of late malignancies...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485156/in-2022-which-is-preferred-haploidentical-or-cord-transplant
#15
JOURNAL ARTICLE
Arnon Nagler, Mohamad Mohty
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk hematological malignancies such as acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Alternative donor transplantation from either haploidentical (haplo-SCT) or cord blood donor (CBT) is an established therapeutic alternative for patients who need transplants but lack a human leukocyte antigen-matched donor. Although haplo-SCT (mainly non-T-cell-depleted haplo-SCT with posttransplant cyclophosphamide) is increasing while CBT is decreasing worldwide (Figure 1), recent developments in CBT, especially cord blood expansion and other strategies to improve engraftment and immune reconstitution post-CBT, make CBT still a valuable option...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485155/epidemiology-and-treatment-of-priapism-in-sickle-cell-disease
#16
JOURNAL ARTICLE
Ibrahim M Idris, Arthur L Burnett, Michael R DeBaun
Ischemic priapism is a common but underrecognized morbidity affecting about 33% of adult men with sickle cell disease (SCD). The onset of priapism occurs in the prepubertal period and tends to be recurrent with increasing age. Significantly, priapism is associated with an unrecognized high burden of mental duress and sexual dysfunctions. The diagnosis of priapism is clinical. Many episodes of priapism will resolve spontaneously, but when an episode lasts longer than 4 hours, the episode is considered a urologic emergency requiring quick intervention with either corporal aspiration or shunt surgery...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485154/no-crystal-stair-supporting-fertility-care-and-the-pursuit-of-pregnancy-in-women-with-sickle-cell-disease
#17
JOURNAL ARTICLE
Lydia H Pecker, Alecia Nero, Mindy Christianson
Growing recognition that the ovary is an end organ in sickle cell disease (SCD), advances in SCD treatment and cure, and innovations in assisted reproductive technologies invite progressive challenges in fertility care for women with SCD. The reproductive life span of women with SCD may be reduced because ovarian reserve declines more rapidly in people with SCD compared to unaffected people. Some young women have diminished ovarian reserve, a risk factor for infertility. Referrals for fertility preservation may be offered and anticipatory guidance about when to seek infertility care provided...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485153/novel-therapies-and-combinations-in-cll-refractory-to-btk-inhibitors-and-venetoclax
#18
JOURNAL ARTICLE
Lydia Scarfò
Patients with chronic lymphocytic leukemia (CLL) refractory to covalent BTK and BCL2 inhibitors have a new unmet clinical need. Standard treatment options are able to obtain only limited and short-lasting disease control associated with reduced overall survival, and thus these patients have become ideal candidates for enrollment in clinical trials. Favorable results have been obtained with the use of noncovalent BTK inhibitors (roughly 70% overall response rate regardless of the actual resistance or intolerance to previous covalent BTK inhibitors) and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (with complete responses in up to 45% of cases and an undetectable measurable residual disease rate of 65% in the bone marrow)...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485152/selecting-initial-therapy-in-cll
#19
JOURNAL ARTICLE
Inhye E Ahn, Jennifer R Brown
Targeted therapy is a powerful treatment option in chronic lymphocytic leukemia (CLL) that has outperformed conventional chemoimmunotherapy in most clinical settings. Except for selected young, fit patients with a mutated immunoglobulin heavy chain variable region gene, most patients benefit from targeted therapy with either a continuous BTK inhibitor or 1-year fixed-duration venetoclax-obinutuzumab as first-line treatment of CLL. Treatment selection is driven by patient-, treatment-, and disease-related factors, encompassing patient preference, concomitant medications, comorbidities, safety profile of the regimen, and TP53 aberration...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/36485151/anticoagulant-therapy-for-women-implications-for-menstruation-pregnancy-and-lactation
#20
JOURNAL ARTICLE
Emma DeLoughery, Bethany Samuelson Bannow
Estrogen exposure, in the setting of pregnancy, the postpartum state, combined hormonal contraceptives (CHCs), or hormone therapy use, has been clearly associated with increased rates of venous thromboembolism (VTE). Although recurrence rates are low in these settings, up to 70% of anticoagulated menstruating individuals experience abnormal or heavy menstrual bleeding (HMB), which commonly results in iron deficiency with or without anemia. Patients taking rivaroxaban appear to experience higher rates of HMB compared with those on apixaban, dabigatran, or warfarin...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
journal
journal
34720
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.